Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors

Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1. doi: 10.5414/cpp40580.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / pharmacokinetics
  • Benzenesulfonates / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Maximum Tolerated Dose
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism
  • Neoplasms / metabolism
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Phosphorylation
  • Proto-Oncogene Proteins c-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-raf / metabolism
  • Pyridines / adverse effects
  • Pyridines / pharmacokinetics
  • Pyridines / pharmacology*
  • Sorafenib

Substances

  • Benzenesulfonates
  • Enzyme Inhibitors
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Proto-Oncogene Proteins c-raf
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases